Atea Pharmaceuticals Inc (NAS:AVIR)
$ 3.71 -0.25 (-6.31%) Market Cap: 312.47 Mil Enterprise Value: -242.18 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 43/100

Atea Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 04:55PM GMT
Release Date Price: $7.17 (-10.15%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Good afternoon, everybody. Thanks for joining us for the next session. Really pleased to have Atea with us for the next session. Just quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. So JP, I'm going to turn it over to you to make some opening comments, and then we can jump right into it.

Jean;Pierre Sommadossi
Atea Pharmaceuticals, Inc. - Founder, Chairman, CEO & President

Well, first, thank you, Matt, to us and to give us the opportunity to give the latest update on our pipeline. Since the founding of the company in 2014, our vision has been centered on the discovery and development of antivirus. So the treatment (inaudible) prophylaxis of the most severe viral diseases where there is a major unmet medical need or where we can really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot